Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel

Abstract

It has been verified that carvedilol can attenuate myocardial no-reflow. However, the effects of carvedilol on adenosine triphosphate-sensitive K⁺ (K_ATP) channel and endothelin-1 (ET-1) are unknown. Forty mini-swines were randomized into 5 study groups: 8 control, 8 carvedilol pretreatment, 8 glibenclamide (K_ATP channel blocker)-treated, 8 carvedilol and glibenclamide-pre-treated and 8 sham-operated. An acute myocardial infarction(AMI) and reperfusion model was created with a three-hour occlusion of the left anterior descending coronary artery followed by one-hour reperfusion. Compared with the control group, carvedilol significantly decreased the area of no-reflow (myocardial contrast echocardiography: from 78.5±4.5% to 24.9±4.1%, pathological means: from 82.3±1.9% to 25.8±4.3% of ligation area, respectively; all p < 0.01) and reduced necrosis size from 98.5±1.3% to 74.4±4.7% of ligation area, p < 0.05). It also decreased plasma ET-1 and myocardial tissue ET-1. However, glibenclamide abrogated the protective effect of carvedilol. The beneficial effect of carvedilol on myocardial no-reflow could be due to its effect on ET-1 via the activation of the K_ATP channel.

Keywords

acute myocardial infarction carvedilol reperfusion

Get full access to this article

View all access options for this article.

References

1 Kelly RV Cohen MG Runge MS . The no-reflow phenomenon in coronary arteries . J Thromb Haemostasis 2004; 2: 1903 – 1907 .

2 Wu KC Zerhouni EA Judd RM . Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction . Circulation 1998; 97: 765 – 772 .

3 Swinburn JM Lahiri A Senior R . Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction . J Am Coll Cardiol 2001; 38: 19 – 25 .

4 Reffelmann T Kloner RA . The "no-reflow" phenomenon: basic science and clinical correlates . Heart 2002; 87: 162 – 168 .

5 Zhao JL; Yang YJ; You SJ; . Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol 2006 Jul 3; [Epub ahead of print]

6 Kloner RA Ganote CE Jennings RB . The “no-reflow” phenomenon after temporary coronary occlusion in the dog . J Clin Invest 1974; 54: 1496 – 1508 .

7 Wainstein MV; Goncalves SC; Zago AJ; . Plasma endothelin-1 levels after coronary stenting in humans. Am J Cardiol 2003, 15; 92: 1211–1214.

8 Galatius S Wroblewski H Sorensen VB . Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation . Am Heart J 1999; 137(3): 549 – 554 .

9 Gande S Miura T Miki T Ichikawa Y Shimamoto KK . (ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia . J Am Coll Cardiol 2002; 40: 1339 – 1346 .

10.

10 Chen XC Zhang XM Luo NS Fang C Liu YM Wu W . Effects of endothelin receptor A antagonist FR139317 on rats with congestive heart failure . Acta Pharmacol Sin. 2001; 22: 896 – 900 .

11.

11 Bradford MM . A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding . Anal Biochem 1976; 72: 248 – 254 .

12.

12 Saxenhofer H Morger D Weidmann P . Modulation of noradrenergic but not angiotensinergic blood pressure control by beta-blockade with carteolol . J Hypertens 1991; 9: 1049 – 1056 .

13.

13 Silke B Verma SP Hussain M . Haemodynamic dose–response effects of i.v. penbutolol in angina pectoris . Br J Clin Pharmacol 1983; 16: 529 – 535 .

14.

14 Packer M Coats AJ Fowler MB . Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med. 2001; 344: 1651 – 1658 .

15.

15 Dargie HJ . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial . Lancet 2001; 357: 1385 – 1390 .

16.

16 Manciet LH Poole DC McDonagh PF . Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon . Am J Physiol 1994; 266: H1541 – H1550 .

17.

17 Gavin JB Thomson RW Humphrey SM . Changes in vascular morphology associated with the no-reflow phenomenon in ischemic myocardium . Virchows Arch 1983; 399: 325 – 332 .

18.

18 Yanagisawa M Kurihara H Kimura S . A novel potent vasoconstrictor peptide produced by vascular endothelial cells . Nature 1988; 332: 411 – 415 .

19.

19 Niccoli G Lanza GA Shaw S . Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization . Eur Heart J 2006; 27: 1793 – 1798 .

20.

20 Ohlstein EH Arleth AJ Storer B . Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells . J Mol Cell Cardiol 1998; 30: 167 – 173 .